Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Sonya Johnson, 41, started taking drugs at age 11, when a man who was sexually abusing her gave them to her behind her ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Mental health has not always been talked about within communities of color, but that is starting to shift because of people ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

Republican Wisconsin Sen. Ron Johnson is sounding the alarm about the deficit impact of President Donald Trump’s “big, ...

Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged more than 46% to a record low on Monday as the ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

After nearly a decade of friendship built on the power of music, Dwayne “The Rock” Johnson and Jelly Roll finally got to meet ...